After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
The real story is in the stocks the pros hate.
There is no shortage of opinions and politics as the House prepares for a vote Nov. 30 on 21st Century Cures Act.
The stock will eventually rebase, but we don't know where or when.
Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.